Pigmentary Disorders

Pigmentary disorders of the skin can be the cause of significant psychological distress in affected patients.

At the SDPA 2022 Annual Summer Dermatology Conference, a session on both common and rare dermatological disorders.

Ruxolitinib cream 1.5% may soon be the first FDA-approved treatment for repigmentation of vitiligo. Experts share what dermatologists need to know regarding efficacy, safety, and cost of this topical drug.

The skincare manufacturer and distributer announced that it has received patents for hair growth and melasma.

In a presentation at the current AAD annual meeting, experts discussed differential diagnoses and clinical presentations in birthmarks and hamartomas.

Investigator Loren Krueger, MD, urges dermatologists to recognize and correct disparities in clinical decision-making, particularly regarding skin cancer.

Unsafe and toxic skin-whitening products continue to draw fire.

Hyperpigmentation requires dermatologists to take a multimodal approach and be familiar with a menu of treatments, according to a presentation given at Maui Derm for Dermatologists 2022, held January 24 to 28, 2022 in Maui Hawaii, and virtual.

The Skin of Color Society released an article detailing its 2021 achievements, containing what the society considers its most active and successful year.

Long underserved by a narrow armamentarium, patients with pigmentary disorders could soon see a new wave of oral and topical solutions to treat even the most challenging cases.

Treating dermatologic conditions in skin of color requires cultural awareness and sensitivity, in addition to being aware of how presentation may differ.

Racial disparities in antibiotic prescription also influence treatment decisions.

Investigators reported a significant difference in the expansion rate of the skin lesion area in patients with vitiligo in just 3 months of treatment.

Investigators write that methods such as dermatoscopy can result in early recognition of unstable patches and lead to appropriate medical treatment for patients with vitiligo.

A new study showed about half of all vitiligo patients from a care system were burdened with the sleeping disorder.

In this first part of our coverage of “The Skin of Color Update Pre-Conference Virtual Symposium” held August 3, we review challenging cases of melasma, vitiligo, and post-inflammatory hyperpigmentation in skin of color patients.

Camp Wonder, a camp that supports kids with skin disease and is sponsored by Galderma, is celebrating their 20th year of operations this week.

Arcutis Biotherapeutics announced early termination of its phase 2a trial evaluating ARQ-252 as a potential treatment for vitiligo citing to inadequate local drug delivery to the skin.

The COVID-19 pandemic had forced vitiligo patients to delay treatments; however, not much is known about the effects of delaying on disease course.

Ruxolitinib cream (Jakafi, Incyte) demonstrated positive results in 2 phase 3 studies investigating the topical for treatment of vitiligo in patients 12 years and older

Incyte's Phase 2 study evaluating ruxolitinib cream for vitiligo meets primary endpoint, shows improvement in body and facial repigmentation compared to placebo.

A study published by the American Society of Laser Medicine and Surgery reveals the efficacy of the 755-nm picosecond laser as a treatment for melasma in Asian women with darker skin types.

AVITA Therapeutics has launched a study evaluating their RECELL System as a treatment for stable vitiligo.

New research has shed light on how hyperpigmentation occurs. Experts break down what you need to know in this article.

Newer and emerging modalities are addressing the need for better therapeutic options for vitiligo, but there remains a broader need for dermatologists to understand the existing, useful therapies for this disfiguring, but undertreated autoimmune condition.

Vitiligo affects 3 million people of all skin types per year in the U.S. In this article, Dr. Wheeland summarizes the latest updates on vitiligo, highligting promising treatments to come.

New consensus conclusions are important, because managing acquired macular pigmentation is a new frontier in dermatology. The article defines terminology and notes the primary feature common to macular pigmentation conditions.

Do you know the warning signs of life threatening purpura? Dr. Roderick Hay outlines what you need to know about potentially life-threatening conditions involving purpura.

The latest roundup of new dermatology products includes safe ultrasound treatment in the home, skincare for aging skin, and topical pain relief.